Stock Alert: Ardelyx Down 6%

Shares of Ardelyx, Inc. (ARDX) slipped nearly 6% on Tuesday morning despite no negative stock-related news.

ARDX is currently trading at $5.88, down $0.36 or 5.84%, on the Nasdaq.

The company announced that FDA accepted its New Drug Application of tenapanor for the control of serum phosphorus in adult chronic kidney disease patients. The FDA has set a Prescription Drug User Fee Act goal date of April 29, 2021.

CEO Mike Raab said, "With potential approval in the second quarter of 2021, we continue to advance commercial preparations for the launch of tenapanor, a first-in-class, non-binder therapy that targets the primary pathway of phosphorus absorption."

Tenapanor reduces serum phosphate by inhibiting a protein called sodium/hydrogen exchanger 3 that plays a key role in phosphate absorption in the gut via a pathway called passive paracellular flux which occurs between cells.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Financial services firm Morgan Stanley (MS) reported Wednesday a profit for the fourth quarter that increased 10 percent from last year, reflecting 7 percent revenue growth amidst strength in Wealth Management and Investment Management business segments. Bank of America Corp. (BAC) reported Thursday that net income applicable to common shareholders for the fourth quarter grew 30 percent to $6.77 billion from last year's $5.21 billion, with earnings per share increasing to $0.82 from $0.59 in the prior year, reflecting strong operating leverage as revenues... Shares of ASML Holding N.V. were gaining more than 1 percent in Amsterdam trading after the Dutch semiconductor equipment maker reported Wednesday higher profit and net sales in its fourth quarter. The company also projects higher sales in fiscal 2022, and a 100 percent increase in total dividend.
Follow RTT